Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : ForDoz
Deal Size : Undisclosed
Deal Type : Agreement
LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®
Details : LipoMedix's lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex inje...
Brand Name : Promitil
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : ForDoz
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : ForDoz
Deal Size : Undisclosed
Deal Type : Agreement
ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix
Details : Fordoz will support LipoMedix to develop and manufacture Promitil in the United States. Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemor...
Brand Name : Promitil
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : ForDoz
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Promitil,Capecitabine,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 23, 2020
Lead Product(s) : Promitil,Capecitabine,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?